Back to top
more

Agios Pharmaceuticals, Inc. (AGIO)

(Delayed Data from NSDQ)

$33.07 USD

33.07
1,382,312

-0.67 (-1.99%)

Updated Oct 18, 2019 03:56 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | F Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study

Agios' (AGIO) Tibsovo improves progression free survival and reduces risk of disease progression or death in a phase III study in previously treated patients with IDH1 mutant cholangiocarcinoma.

AZN LLY AGIO CELG

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Down 11.2% Since Last Earnings Report: Can It Rebound?

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGIO

Zacks Equity Research

Agios Rides High on Tibsovo Sales Amid Acute Competition

Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.

AZN LLY AGIO CELG

Zacks Equity Research

Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales

Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.

AGIO ACOR CELG RGEN

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -8.09% and 6.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AGIO

Zacks Equity Research

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AGIO

Zacks Equity Research

Agios (AGIO) Catches Eye: Stock Jumps 5.4%

Agios (AGIO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

AGIO HAE

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Down 8% Since Last Earnings Report: Can It Rebound?

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGIO

Zacks Equity Research

Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study

Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.

AGIO GILD CELG MRUS

Zacks Equity Research

Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1

Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.

AGIO PDLI CELG MRUS

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.62% and 38.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AGIO

Zacks Equity Research

Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AGIO

Zacks Equity Research

AVEO Reports Positive Results on Leukemia Drug, Shares Up

AVEO Oncology (AVEO) reports positive results from phase Ib study of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia.

LLY AGIO CELG AVEO

Zacks Equity Research

Agios (AGIO) Surges More Than 40% Year to Date: Here's Why

Agios' (AGIO) first wholly owned precision medicine, Tibsovo, has been picking up the sales pace since its FDA approval last year with strong sequential growth delivered in Q4.

AGIO PDLI KMDA CELG

Zacks Equity Research

Agios Gains Breakthrough Therapy Status for Tibsovo Combo

Agios (AGIO) receives a Breakthrough Therapy designation for Tibsovo combo to treat the newly diagnosed acute myeloid leukemia in adult patients with an IDH1 mutation.

AGIO PDLI CELG KMDA

Zacks Equity Research

Why Is Agios Pharmaceuticals (AGIO) Up 13.2% Since Last Earnings Report?

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGIO

Zacks Equity Research

Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer

Agios' (AGIO) label expansion filing eyes an approval of Tibsovo for newly diagnosed acute myeloid leukemia patients with an IDH1 mutation. The drug also gets a priority review tag from the FDA.

AGIO BDSI CELG PRQR

Zacks Equity Research

Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock

Agios' (AGIO) loss tops estimates in Q4. Its precision medicine Tibsovo receives the FDA nod and leads to significant year-over-year revenue growth.

AGIO CELG BDSI SNSS

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 4.24% and 42.84%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

AGIO

Zacks Equity Research

Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AGIO

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Down 4% Since Last Earnings Report: Can It Rebound?

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGIO

Zacks Equity Research

Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock

Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.

AGIO CELG GILD CLBS

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 3.55% and 8.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

AGIO

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Q3 Earnings Preview: Here's What to Look Out For

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AGIO

Zacks Equity Research

Agios Rides on Tibsovo Approval Amid Reliance on Celgene

Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.

AZN MRK AGIO CELG